
Akebia Therapeutics (AKBA) P/E Ratio
P/E Ratio as of Jul 2, 2025: -16.87
Average-16.99
Median-16.91
Minimum-18.45
Maximum-15.89
-16.87
Past Month-1.77 (11.72%)
The P/E ratio for Akebia Therapeutics (AKBA) is -16.87 as of Jul 2, 2025. This represents a increase of 88.07% compared to its 12-month average P/E ratio of -8.97. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Akebia Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Akebia Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Akebia Therapeutics to industry peers.
Akebia Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Akebia Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Akebia Therapeutics to industry peers.
Akebia Therapeutics (AKBA) P/E Ratio Insights
See Akebia Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Akebia Therapeutics (AKBA)
Order type
Buy in
Order amount
Est. shares
0 shares
Akebia Therapeutics (AKBA) P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jul 1, 2025 | $3.57 | -16.59 |
Jun 2, 2025 | $3.25 | -15.10 |
May 1, 2025 | $2.39 | -7.28 |
Apr 1, 2025 | $1.91 | -5.82 |
Mar 3, 2025 | $1.80 | -8.16 |
Feb 3, 2025 | $2.12 | -9.61 |
Jan 2, 2025 | $1.90 | -8.61 |
Akebia Therapeutics (AKBA) End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -16.87 | +95.93% |
2024 | -8.61 | +128.38% |
2023 | -3.77 | +471.21% |
2022 | -0.66 | -50.00% |
2021 | -1.32 | +30.69% |
2020 | -1.01 | — |
FAQs About Akebia Therapeutics (AKBA) P/E ratio
The latest P/E ratio of Akebia Therapeutics (AKBA) is -16.87, as of Jul 2, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Akebia Therapeutics’s last 12-month average P/E ratio is -8.97, compared to its current P/E ratio of -16.87. This reflects a increase of 88.07%.
Akebia Therapeutics’s current P/E ratio of -16.87 is higher than its last 12-month average P/E of -8.97. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Akebia Therapeutics’s average P/E ratio over the last 3 years is -4.97. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Akebia Therapeutics’s average P/E ratio over the last 5 years is -3.5. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.